Lupus erythematosus
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Leviter purpureum erythema apparet.
exanthemum papilioniforme quod typice in facie apparet.
relevance score : -100.0%
ReferencesProvocationes diagnosticae distinguentes cutaneous lupus erythematosus (CLE) ponunt, distinguentes eum ab systemic lupus erythematosus cum signis cutaneis. Recentes studia illustrant causas geneticas, ambientales et immunologicas quae CLE afficiunt. Inductio medicamentosa speciatim emersit ut una ex maximis triggeribus pro CLE. Curatio therapiae systemicae implicat, in quibus biologici agentes (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) cum efficacia demonstrata in iudiciis clinicis.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) varias manifestationes cutaneas complectitur, quarum aliquas ad problemata sanitatis latioris ligare posset. Categoria est in diversis generibus, ut acute CLE (ACLE), sub‑acute CLE (SCLE), et chronic CLE (CCLE). CCLE complectitur discoid lupus erythematosus (DLE), LE profundus (LEP), lupus cutaneus perniosis (chilblain cutaneous lupus), et lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus est coetus morborum autoimmunium qui partes corporis afficere possunt. Quaedam genera, sicut systemic lupus erythematosus (SLE), in multis organis impacta sunt, aliae, ut cutaneous lupus erythematosus (CLE), maxime cutem afficiunt. Varias species CLE pono in mixto signorum clinicorum, examinis et textorum sanguine probationum, sed multum variatio inter homines est. Problemata cutis saepe explicantur ex factoribus sicut expositio ad solem (sun exposure), fumum (smoking), aut medicamenta quaedam.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Causa lupus erythematosus non clara est. Inter geminos identicos, si unus affectus est, 24 % probabilitas est alterum etiam affectum fore. Hormones sexus feminei, sol, fumare, defectus vitaminæ D, et quaedam infectiones etiam creduntur augere periculum.
Curationes includunt NSAIDs, corticosteroides, immunosuppressantes, hydroxychloroquinum (hydroxychloroquine) et methotrexatum (methotrexate). Etsi corticosteroides efficaces sunt, usus diuturnus eorum potest causare effectus adversos.